1. Home
  2. CNS vs NUVB Comparison

CNS vs NUVB Comparison

Compare CNS & NUVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cohen & Steers Inc

CNS

Cohen & Steers Inc

N/A

Current Price

$62.53

Market Cap

3.1B

Sector

Finance

ML Signal

N/A

NUVB

Nuvation Bio Inc.

N/A

Current Price

$8.54

Market Cap

2.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CNS
NUVB
Founded
1986
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.9B
IPO Year
2004
N/A

Fundamental Metrics

Financial Performance
Metric
CNS
NUVB
Price
$62.53
$8.54
Analyst Decision
Hold
Strong Buy
Analyst Count
2
8
Target Price
$72.50
$10.63
AVG Volume (30 Days)
539.9K
9.9M
Earning Date
01-21-2026
11-03-2025
Dividend Yield
3.95%
N/A
EPS Growth
18.87
N/A
EPS
3.19
N/A
Revenue
$552,096,000.00
$26,748,000.00
Revenue This Year
$8.26
$609.55
Revenue Next Year
$10.55
$197.91
P/E Ratio
$19.71
N/A
Revenue Growth
11.13
1137.19
52 Week Low
$58.39
$1.54
52 Week High
$100.19
$8.95

Technical Indicators

Market Signals
Indicator
CNS
NUVB
Relative Strength Index (RSI) 46.82 67.31
Support Level $61.95 $8.13
Resistance Level $63.59 $8.95
Average True Range (ATR) 1.60 0.50
MACD 0.35 -0.06
Stochastic Oscillator 68.77 70.46

Price Performance

Historical Comparison
CNS
NUVB

About CNS Cohen & Steers Inc

Cohen & Steers is a niche asset manager concentrating on real estate securities. The firm invests mainly in the equity shares of real estate investment trusts, with holdings in domestic and international real estate securities accounting for around two thirds of its $90.9 billion in managed assets at the end of September 2025. Cohen & Steers also manages portfolios dedicated to preferred securities, utilities stocks, and other high-yield offerings. The firm's distribution is balanced among its closed-end funds, open-end funds, and institutional accounts. During the past four calendar quarters, the company garnered 39% (26%) of its managed assets (base management fees) from institutional clients, 48% (54%) from open-end funds, and 13% (20%) from closed-end funds.

About NUVB Nuvation Bio Inc.

Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor specifically designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes differentiated, novel oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in their different stages of development. The company generates revenue through out-licensing collaborative agreements with its customers located in China and Japan.

Share on Social Networks: